Literature DB >> 10051131

Neuroregulation by vasoactive intestinal peptide (VIP) of mucus secretion in ferret trachea: activation of BK(Ca) channels and inhibition of neurotransmitter release.

Y C Liu1, H J Patel, A M Khawaja, M G Belvisi, D F Rogers.   

Abstract

1. The aims of this study were to determine: (1) whether vasoactive intestinal peptide (VIP) regulates cholinergic and 'sensory-efferent' (tachykininergic) 35SO4 labelled mucus output in ferret trachea in vitro, using a VIP antibody, (2) the class of potassium (K+) channel involved in VIP-regulation of cholinergic neural secretion using glibenclamide (an ATP-sensitive K+ (K(ATP)) channel inhibitor), iberiotoxin (a large conductance calcium activated K+ (BK(ca)) channel blocker), and apamin (a small conductance K(ca) (SK(ca)) channel blocker), and (3) the effect of VIP on cholinergic neurotransmission using [3H]-choline overflow as a marker for acetylcholine (ACh) release. 2. Exogenous VIP (1 and 10 microM) alone increased 35SO4 output by up to 53% above baseline, but suppressed (by up to 80% at 1 microM) cholinergic and tachykininergic neural secretion without altering secretion induced by ACh or substance P (1 microM each). Endogenous VIP accounted for the minor increase in non-adrenergic, non-cholinergic (NANC), non-tachykininergic neural secretion, which was compatible with the secretory response of exogenous VIP. 3. Iberiotoxin (3 microM), but not apamin (1 microM) or glibenclamide (0.1 microM), reversed the inhibition by VIP (10 nM) of cholinergic neural secretion. 4. Both endogenous VIP (by use of the VIP antibody; 1:500 dilution) and exogenous VIP (0.1 microM), the latter by 34%, inhibited ACh release from cholinergic nerve terminals and this suppression was completely reversed by iberiotoxin (0.1 microM). 5. We conclude that, in ferret trachea in vitro, endogenous VIP has dual activity whereby its small direct stimulatory action on mucus secretion is secondary to its marked regulation of cholinergic and tachykininergic neurogenic mucus secretion. Regulation is via inhibition of neurotransmitter release, consequent upon opening of BK(Ca) channels. In the context of neurogenic mucus secretion, we propose that VIP joins NO as a neurotransmitter of i-NANC nerves in ferret trachea.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051131      PMCID: PMC1565792          DOI: 10.1038/sj.bjp.0702288

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  65 in total

1.  Apamin blocks certain neurotransmitter-induced increases in potassium permeability.

Authors:  B E Banks; C Brown; G M Burgess; G Burnstock; M Claret; T M Cocks; D H Jenkinson
Journal:  Nature       Date:  1979-11-22       Impact factor: 49.962

2.  Neuroregulation of mucus secretion by opioid receptors and K(ATP) and BK(Ca) channels in ferret trachea in vitro.

Authors:  S I Ramnarine; Y C Liu; D F Rogers
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

3.  Prostaglandins alter methacholine-induced secretion in ferret in vitro trachea.

Authors:  M E Deffebach; H Islami; A Price; S E Webber; J G Widdicombe
Journal:  Am J Physiol       Date:  1990-02

4.  Localization of VIP-immunoreactive nerves in airways and pulmonary vessels of dogs, cat, and human subjects.

Authors:  R D Dey; W A Shannon; S I Said
Journal:  Cell Tissue Res       Date:  1981       Impact factor: 5.249

5.  Effects of VIP and related peptides on airway mucus secretion from isolated rat trachea.

Authors:  U Wagner; D Bredenbröker; B Storm; B Tackenberg; H C Fehmann; P von Wichert
Journal:  Peptides       Date:  1998       Impact factor: 3.750

6.  Evidence for the involvement of prostaglandins in modulation of acetylcholine release from canine bronchial tissue.

Authors:  I A Deckers; M Rampart; H Bult; A G Herman
Journal:  Eur J Pharmacol       Date:  1989-08-29       Impact factor: 4.432

7.  ATP-sensitive K-channels in HIT T15 beta-cells studied by patch-clamp methods, 86Rb efflux and glibenclamide binding.

Authors:  I Niki; R P Kelly; S J Ashcroft; F M Ashcroft
Journal:  Pflugers Arch       Date:  1989-10       Impact factor: 3.657

8.  Nitric oxide inhibition of basal and neurogenic mucus secretion in ferret trachea in vitro.

Authors:  S I Ramnarine; A M Khawaja; P J Barnes; D F Rogers
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

9.  Inhibition by vasoactive intestinal peptide of glycoconjugate and lysozyme secretion by human airways in vitro.

Authors:  S J Coles; S I Said; L M Reid
Journal:  Am Rev Respir Dis       Date:  1981-11

10.  Effects of peptidases on non-adrenergic, non-cholinergic inhibitory responses of tracheal smooth muscle: a comparison with effects on VIP- and PHI-induced relaxation.

Authors:  J L Ellis; S G Farmer
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

View more
  5 in total

1.  Mucus secretion from individual submucosal glands of the ferret trachea.

Authors:  Hyung-Ju Cho; Nam Soo Joo; Jeffrey J Wine
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-04-30       Impact factor: 5.464

2.  Effect of vasoactive intestinal peptide (VIP)-related peptides on cholinergic neurogenic and direct mucus secretion in ferret trachea in vitro.

Authors:  Y C Liu; A M Khawaja; D F Rogers
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

3.  Role of parasympathetic nerves and muscarinic receptors in allergy and asthma.

Authors:  Gregory D Scott; Allison D Fryer
Journal:  Chem Immunol Allergy       Date:  2012-06-26

4.  PKA-dependent activation of the vascular smooth muscle isoform of KATP channels by vasoactive intestinal polypeptide and its effect on relaxation of the mesenteric resistance artery.

Authors:  Yang Yang; Yun Shi; Shouli Guo; Shuang Zhang; Ningren Cui; Weiwei Shi; Daling Zhu; Chun Jiang
Journal:  Biochim Biophys Acta       Date:  2007-09-12

5.  A Comparative Peptidomic Characterization of Cultured Skeletal Muscle Tissues Derived From db/db Mice.

Authors:  Yanting Wu; Mei Han; Yan Wang; Yao Gao; Xianwei Cui; Pengfei Xu; Chenbo Ji; Tianying Zhong; Lianghui You; Yu Zeng
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-29       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.